Association of reproductive factors with acute myocardial infarction in young women: A VIRGO and NHANES case-control study Authors: Weilai Dong, Huanhuan Yang, Mitsuaki Sawano, Shu-Xia Li, Xiao Xu, Karthik Murugiah, Harlan M. Krumholz, Yuan Lu Published: 2027 ABSTRACT ObjectiveYoung women with acute myocardial infarction (AMI) often present with distinct risk profiles compared with older women and men, but the role of reproductive factors remains poorly understood. This study examines associations of reproductive factors with AMI in young women.MethodsWe conducted a case-control study of 1561 women aged 18–55 years with AMI from VIRGO and age-matched controls from NHANES. A wide range of reproductive factors were evaluated. Conditional logistic regression estimated odds ratios for AMI, sequentially adjusted for race/ethnicity, socioeconomic variables, and traditional risk factors. Stratified analyses were performed by menopausal status.ResultsEarly menarche (<11 years; OR 2.07, 95% CI 1.56–2.73), menopause (OR 1.82, 95% CI 1.50–2.22), gestational diabetes (OR 1.65, 95% CI 1.23–2.19), birth control pills use for 1–5 years (OR 1.67, 95% CI 1.36–2.05), and ever use of female hormones (OR 1.99, 95% CI 1.62–2.46) were associated with higher odds of AMI, while first live birth at ≥30 years (OR 0.50, 95% CI 0.36–0.69), breastfeeding ≥1 month (OR 0.46, 95% CI 0.38–0.56), and current contraceptive use (OR 0.49, 95% CI 0.32–0.76) were associated with lower odds. After adjustment for traditional risk factors, birth control pills use for 1–5 years (OR 1.71, 95% CI 1.25–2.34) and female hormone use (OR 1.75, 95% CI 1.28–2.38) remained significantly associated. Associations varied by menopausal status.ConclusionReproductive factors are associated with early-onset AMI in young women. Recognition of reproductive history may inform prevention strategies in young women. Central Illustration. Central Illustration. Introduction Young women who experience acute myocardial infarction (AMI) represent a particularly vulnerable population: they are less common than older patients but face disproportionately high morbidity, mortality, and long-term disability. Unlike in older age groups, the steady decline in AMI incidence and outcomes seen over the past decades has not extended to young women under 55 years age [[1], [2], [3]]. Young women have a distinct risk profile and bear more nonconventional risk factors for AMI compared to men and older women [[4], [5], [6], [7], [8], [9], [10]]. Reproductive milestones and exposures—including age at menarche, age at first birth, parity, pregnancy complications, breastfeeding, age at menopause, and use of exogenous hormones—have each been linked to cardiovascular outcomes [4,[11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]]. Young women may be more susceptible to reproductive factors due to the temporal proximity to exposure and active hormonal fluctuations. However, the contribution of reproductive factors to AMI in young women has not been systematically studied. Prior studies have been limited by small sample sizes, incomplete reproductive data, lack of distinction between premenopausal and postmenopausal status, and insufficient adjustment for traditional and socioeconomic risk factors [24,25,32]. To address these gaps, we conducted a case-control study including early-onset AMI patients from the multicenter VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) study [33] and population-based control subjects from the NHANES (National Health and Nutrition Examination Survey) study [34]. We aim to identify reproductive factors that may capture sex-specific biological and cardiometabolic trajectories and may help identify women at elevated risk for early-onset AMI. To the best of our knowledge, this study is the largest U.S.-based study to evaluate reproductive factors in young women with AMIs. Methods Study population The VIRGO study included 1870 young women (aged 18 to 55 years) with AMI from 103 hospitals in the US from August 2008 to January 2012. Participants were included if they had elevated cardiac biomarkers (at least 1 biomarker [troponin I or T or creatine kinase-MB] > 99th percentile of upper reference limit) within 24 h of admission. Additional evidence of AMI included either symptoms of ischemia or electrocardiographic changes indicative of new ischemia. Patients with prior AMI were excluded, leaving 1561 participants in this analysis (Fig. 1).Fig. 1Sample inclusion and workflow. Sample inclusion and workflow. The NHANES study provides nationally representative health and nutritional status data for the civilian, noninstitutionalized US population, derived from a complex, multistage probability sampling design, with data collected through standardized interviews, physical examinations, and laboratory testing [34]. To match the VIRGO participants enrollment period, we included female participants from three rounds of NHANES conducted between 2007 and 2012 (2007–2008, 2009–2010, 2011–2012) and excluded individuals with self-reported history of coronary heart disease, angina or angina pectoris, MI, or stroke (Fig. 1). Participants from the VIRGO (cases) and NHANES (controls) studies were matched 1:1 based on age at the time of study enrollment. For stratified analyses, matching was performed separately within each subgroup. Specifically, for menopausal status stratification, cases and controls were matched 1:1 by both age and menopausal status (reached vs not reached menopause). Data collection In both the VIRGO and NHANES studies, in-person interviews were conducted by trained interviewers to collect participants’ information on demographic characteristics, cardiovascular diseases, and reproductive factors. Information on traditional risk factors were collected based on both in-person interviews and review of medical records. Variable definitions Reproductive factors assessed in this study included menopause status, age of menopause, reproductive lifespan, ever been pregnant, number of pregnancies, number of live births, age at first live birth, breastfeeding for at least one month, diabetes during pregnancy, use of birth control pills, and use of female hormones. Details on how reproductive factors were defined in VIRGO and NHANES are provided in Supplementary Table 1. Female hormones were defined as any forms of female hormones excluding birth control methods or use for infertility. These reproductive factors were chosen carefully to focus on those with reasonable consistency in definition between the two cohorts. Factors that were available in only one cohort were excluded from the analysis. Continuous reproductive variables were further categorized based on their nonlinear associations with AMI risk observed in restricted cubic spline plots (Supplementary Figure 1) and supported by literature [[35], [36], [37], [38]]. Traditional risk factors, including hypertension, hyperlipidemia, chronic diabetes, current smoking, and body mass index (BMI), as well as socioeconomic factors, including marital status, highest education level, and household income, were defined as previously described [6] (Supplementary Table 2). Statistical analysis Patient characteristics were compared between the two groups using chi-square tests for categorical variables and Student’s t tests for continuous variables. Associations between reproductive factors and AMI were assessed using univariable conditional logistic regression. Race and ethnicity, socioeconomic factors, and traditional risk factors were included as covariates, while age was not included because it was accounted for by matching. Multivariable analyses were additionally performed excluding collinear variables (Cramér’s V > 0.5), guided by clinical relevance. Exploratory subgroup analyses were performed stratified by menopausal status (reached menopause vs. not reached menopause). Patients in the control group with >40% missing reproductive data were excluded prior to matching to control for percent of missing values for each variable < 10%. Patients who were excluded had a similar distribution of age, race and ethnicity, and cardiovascular disease compared with those retained (Supplementary Figure 2). After exclusion, all variables had <10% missing values in both cases and controls. Missing categorical values were imputed using the most common category, and missing continuous values were imputed using the median. Statistical significance was defined as P < .05 based on 2-sided tests. Bonferroni correction was applied for multiple comparisons. All analyses were conducted in R. The project received IRB approval at all participating sites and followed the STROBE guidelines. Results Cohort characteristics Overall, 1561 women with early-onset AMI from the VIRGO study (1335 (85.5%) with MI-CAD and 194 (12.4%) with MINOCA) and 1561 age-matched controls from the NHANES study were included. Their baseline characteristics are shown in Table 1. The mean (standard deviation: SD) age was 47.1 (6.3) years for VIRGO participants and 47.0 (6.3) years for matched NHANES participants. VIRGO AMI patients had a higher proportion of non-Hispanic White (72.6% vs. 43.0%) and a lower proportion of Hispanic/Latino (4.5% vs. 29.5%) compared with age-matched NHANES participants. Additionally, VIRGO AMI patients had a higher mean BMI (32.2 vs. 30.0kg/m²) and a higher prevalence of hypertension (62.7%v s. 30.0%), hyperlipidemia (81.7% vs. 72.0%), diabetes (37.2% vs. 11.9%), and current smoking (59.8% vs. 22.3%) .Table 1Characteristics of study population.VIRGO AMI Cases (N = 1561)NHANES Controls (N = 1561)P-valueDemographicsAge (mean (SD))47.06 (6.33)47.02 (6.28)0.838Race and ethnicityHispanic71 (4.5)461 (29.5)<0.001Non-Hispanic White1133 (72.6)671 (43.0)Non-Hispanic Black294 (18.8)343 (22.0)Other63 (4.0)86 (5.5)Socioeconomic factorsMarried/living with a partner838 (53.7)989 (63.4)<0.001EducationLess than high school20 (1.3)435 (27.9)<0.001High school627 (40.2)328 (21.0)More than high school914 (58.6)798 (51.1)Annual househould income, $<10 000304 (19.5)95 (6.1)<0.00110 000–99 0001107 (70.9)1202 (77.0)≥100 000150 (9.6)264 (16.9)Traditional risk factorsHypertension978 (62.7)469 (30.0)<0.001Hyperlipidemia1275 (81.7)1124 (72.0)<0.001Diabetes580 (37.2)185 (11.9)<0.001Current smoker933 (59.8)348 (22.3)<0.001BMI32.23 (8.55)29.98 (7.57)<0.001Reproductive factorsAge of menarche<11211 (13.5)124 (7.9)<0.00111–151225 (78.5)1319 (84.5)≥16125 (8.0)118 (7.6)Reached menopause (%)824 (52.8)628 (40.2)<0.001Age of menopause (%)<40208 (25.2)157 (25.0)0.45740–44182 (22.1)120 (19.1)45–55434 (52.7)351 (55.9)Reproductive lifespan (%)<30295 (35.0)216 (34.2)0.78430–39495 (58.6)380 (60.1)≥4054 (6.4)36 (5.7)Ever been pregnant (%)1391 (89.1)1444 (92.5)0.001Number of pregnancies (%)0170 (10.9)117 (7.5)<0.0011–2588 (37.7)506 (32.4)3–4586 (37.5)620 (39.7)≥5217 (13.9)318 (20.4)Number of live births (%)0230 (14.7)184 (11.8)<0.0011–2809 (51.8)748 (47.9)3–4458 (29.3)518 (33.2)≥564 (4.1)111 (7.1)Age of first live birth (%)<20472 (35.5)426 (30.8)<0.00120–29750 (56.3)764 (55.2)≥30109 (8.2)195 (14.1)Breastfeeding at least 1mon (%)563 (42.3)842 (60.8)<0.001Diabetes during pregnancy (%)202 (14.5)128 (8.9)<0.001Ever taking birth control pills (%)1256 (80.5)1216 (77.9)0.086Currently taking birth control pills (%)41 (2.6)62 (4.0)0.045Length of taking birth control pills years (%)≤1501 (32.1)718 (46.0)<0.001>1 & ≤5510 (32.7)378 (24.2)>5 & ≤10307 (19.7)255 (16.3)>10243 (15.6)210 (13.5)Ever taking female hormone (%)401 (25.7)197 (12.6)<0.001 Table 1Characteristics of study population.VIRGO AMI Cases (N = 1561)NHANES Controls (N = 1561)P-valueDemographicsAge (mean (SD))47.06 (6.33)47.02 (6.28)0.838Race and ethnicityHispanic71 (4.5)461 (29.5)<0.001Non-Hispanic White1133 (72.6)671 (43.0)Non-Hispanic Black294 (18.8)343 (22.0)Other63 (4.0)86 (5.5)Socioeconomic factorsMarried/living with a partner838 (53.7)989 (63.4)<0.001EducationLess than high school20 (1.3)435 (27.9)<0.001High school627 (40.2)328 (21.0)More than high school914 (58.6)798 (51.1)Annual househould income, $<10 000304 (19.5)95 (6.1)<0.00110 000–99 0001107 (70.9)1202 (77.0)≥100 000150 (9.6)264 (16.9)Traditional risk factorsHypertension978 (62.7)469 (30.0)<0.001Hyperlipidemia1275 (81.7)1124 (72.0)<0.001Diabetes580 (37.2)185 (11.9)<0.001Current smoker933 (59.8)348 (22.3)<0.001BMI32.23 (8.55)29.98 (7.57)<0.001Reproductive factorsAge of menarche<11211 (13.5)124 (7.9)<0.00111–151225 (78.5)1319 (84.5)≥16125 (8.0)118 (7.6)Reached menopause (%)824 (52.8)628 (40.2)<0.001Age of menopause (%)<40208 (25.2)157 (25.0)0.45740–44182 (22.1)120 (19.1)45–55434 (52.7)351 (55.9)Reproductive lifespan (%)<30295 (35.0)216 (34.2)0.78430–39495 (58.6)380 (60.1)≥4054 (6.4)36 (5.7)Ever been pregnant (%)1391 (89.1)1444 (92.5)0.001Number of pregnancies (%)0170 (10.9)117 (7.5)<0.0011–2588 (37.7)506 (32.4)3–4586 (37.5)620 (39.7)≥5217 (13.9)318 (20.4)Number of live births (%)0230 (14.7)184 (11.8)<0.0011–2809 (51.8)748 (47.9)3–4458 (29.3)518 (33.2)≥564 (4.1)111 (7.1)Age of first live birth (%)<20472 (35.5)426 (30.8)<0.00120–29750 (56.3)764 (55.2)≥30109 (8.2)195 (14.1)Breastfeeding at least 1mon (%)563 (42.3)842 (60.8)<0.001Diabetes during pregnancy (%)202 (14.5)128 (8.9)<0.001Ever taking birth control pills (%)1256 (80.5)1216 (77.9)0.086Currently taking birth control pills (%)41 (2.6)62 (4.0)0.045Length of taking birth control pills years (%)≤1501 (32.1)718 (46.0)<0.001>1 & ≤5510 (32.7)378 (24.2)>5 & ≤10307 (19.7)255 (16.3)>10243 (15.6)210 (13.5)Ever taking female hormone (%)401 (25.7)197 (12.6)<0.001 Characteristics of study population. Association of reproductive factors with early-onset AMI In the association analysis adjusted for race and ethnicity using Model 1, early menarche (<11 years of age; OR 2.07, 95% CI 1.56–2.73), reached menopause (OR 1.82, 95% CI 1.50–2.22), gestational diabetes (OR 1.65, 95% CI 1.23–2.19), use of birth control pills for 1–5 years (OR 1.67, 95% CI 1.36–2.05), and ever taking female hormone (OR 1.99, 95% CI 1.62–2.46) were significantly associated with higher odds of early-onset AMI (Fig. 2). In contrast, having a first live birth at age ≥ 30 years (OR 0.50 compared to having a first live birth at age 20–29 years, 95% CI 0.36–0.69), breastfeeding at least 1 month (OR 0.46, 95% CI 0.38–0.56), and current use of birth control pills (OR 0.49, 95% CI 0.32–0.76) were significantly associated with lower odds of early-onset AMI (Fig. 2).Fig. 2Association of reproductive factors with early-onset AMI in women. Association of reproductive factors with early-onset AMI in women. Additional adjustment for socioeconomic factors in Model 2 did not materially change the direction or magnitude of these associations (Fig. 2). However, after additional adjustment for traditional cardiovascular risk factors in Model 3, including hypertension, hyperlipidemia, diabetes, current smoker, and BMI, most associations were attenuated while the use of birth control pills for 1–5 years (OR 1.71, 95% CI 1.25–2.34) and ever use of female hormones (OR 1.75, 95% CI 1.28–2.38) remained significantly associated with an elevated AMI risk (Fig. 2, Model 3). Multivariable analyses excluding variables with high pairwise collinearity (Cramér’s V > 0.5), guided by clinical relevance, showed similar odds ratio and consistent directions of association compared to univariable analyses though less significant p-values; Use of birth control pills for 1–5 years showed 1.69-fold higher odds (95% CI 1.17 −2.44) and ever taking female hormone showed 1.61-fold higher odds (95% CI 1.12, 2.23) of early-onset AMI after full adjustment (Supplementary Figure 3 and 4). Difference in risk by menopausal status The distribution of reproductive factors varied by menopause status. Compared with AMI patients who had reached menopause, those at premenopausal status were younger (50.3 vs. 43.2 years, P < 0.001), included a higher proportion of non-Hispanic Black patients and a lower proportion of non-Hispanic White patients, and had higher mean BMI (31.5 vs. 33.1) but lower prevalence of hypertension (67.2% vs. 57.3%), hyperlipidemia (84.0% vs. 78.8%), and current smoking (63.2% vs. 55.6%) (Supplementary Table 3). In exploratory subgroup analyses stratified by menopausal status, after adjustment for race and ethnicity (Fig. 3), early menarche (<11 years), diabetes during pregnancy, and ever taking female hormones showed stronger association among premenopausal women. In contrast, age at first live birth ≥ 30 years and use of birth control pills for 1–5 years were more strongly associated with patients who had reached menopause compared to those who had not.Fig. 3Association of reproductive factors with early-onset AMI in menopausal and non-menopausal women, adjusted by race and ethnicity. Association of reproductive factors with early-onset AMI in menopausal and non-menopausal women, adjusted by race and ethnicity. Discussions This largest U.S. based, case-control study from VIRGO and NHANES provided a comprehensive assessment of reproductive factors associated with early-onset AMI among US women, highlighting several key findings. We identified 8 reproductive factors (early menarche, reached menopause, diabetes during pregnancy, length of use of birth control pills for 1–5 years, ever use of female hormone, having a first live birth at age ≥ 30 years, breastfeeding at least 1 month, and currently taking birth control pills) with significant association of odds of AMI in young women after controlling for race and ethnicity, and 2 factors (length of taking birth control pills, ever use of female hormone) that remained significant after adjustment for traditional risk factors. We also observed heterogeneity of reproductive risk factors by menopausal status. This study extends the field in several important ways. First, few prior studies have comprehensively assessed the association of reproductive factors with AMI among women aged 18 to 55 years. Younger women often present with distinct AMI phenotypes and risk profiles beyond traditional risk factors [6,39]. Our findings demonstrate that early menarche, menopause, and gestational diabetes are associated with increased AMI risk, whereas breastfeeding ≥1 month is associated with reduced risk, consistent with prior studies in women across a broad age range [[13], [14], [15], [16], [17],20,22,32,[40], [41], [42]]. These associations, however, retained after adjusting by socioeconomic factors, but were noted to attenuate after adjustment for traditional risk factors, suggesting that reproductive factors may exert their effect through metabolic pathways. For instance, early menarche is associated with higher lifetime adiposity and metabolic risk [43], and pregnancy complications are linked with later development of hypertension and diabetes [44]. Breastfeeding for at least one month is nominally associated with reduced AMI risk, which may be due to lactation’s capacity to modulate more favorable cardiometabolic profiles through mechanisms such as increasing insulin sensitivity [45], increasing HDL cholesterol [46], and reducing the risk of diabetes [47]. We observed that the duration of taking birth control pills and ever taking other female hormone therapy remained independent risk factors to early-onset AMI after adjustment for race and ethnicity, socioeconomic factors, and traditional risk factors. Most prior studies showed that birth control pills use had no effect or increased the risk of AMI [14,27,48,49], while duration of use showed no significant association [27,48,50]. The impact of female hormone use on AMI is complex. While earlier cohorts such as Women’s Health Initiative (WHI) [51] and Heart and Estrogen/progestin Replacement Study (HERS) [52] demonstrated increased cardiovascular risk with hormone therapy, more contemporary evidence suggests that initiation of hormone therapy within ten years after menopause had lower mortality and fewer cardiac events while initiation >10 years after menopause had no effect on death or CVD outcomes [53]; Notably, the American College of Cardiology Cardiovascular Disease in Women Committee does not recommend hormone therapy for the primary or secondary prevention of cardiovascular disease [54]. However, WHI and HERS studies primarily evaluated oral conjugated equine estrogen 0.625 mg combined with medroxyprogesterone acetate 2.5 mg daily [51,52], and the subsequent meta-analyses evaluated a broad range of moderate-dose oral estrogen formulations with or without progestins [53]. These regimens may differ substantially from hormonal formulations commonly used during the 2008–2012 recruitment period of VIRGO and NHANES with respect to estrogen dose, progestin type, route of administration, timing and duration of exposure, and clinical indications. In addition, contemporary oral contraceptives generally contain substantially lower estrogen doses and different progestin formulations than earlier generations, making direct comparisons with historical studies challenging. Second, we found that the association of reproductive risk factors with early-onset AMI vary by menopausal status. We found that age at first live birth ≥ 30 years and use of birth control pills for 1–5 years were more significantly associated with AMI among postmenopausal women, whereas early menarche, gestational diabetes, and ever taking female hormones appeared more highly associated in premenopausal women. These findings highlight heterogeneity in reproductive risk by menopausal status and may reflect differences in the timing and latency of exposures. Early-life reproductive factors, such as menarche and pregnancy-related complications, may exert effects over shorter time horizons, whereas later-life exposures, such as delayed childbearing, may require longer latency to influence cardiovascular risk. Limitations Our study has limitations. Firstly, we were not able to assess the association of some important reproductive factors with AMI risk as they were not available in VIRGO or NHANES data or were only available in one of them. For instance, VIRGO included regularity of periods, hypertension during pregnancy and preeclampsia, and preterm labor, while NHANES included vaginal versus cesarean deliveries, birth weight, and hysterectomy. Secondly, some variables were not well specified; for example, information on the types or doses of contraceptives and female hormones, as well as initiation timing and indication, was lacking. Thirdly, the questionnaires used in VIRGO and NHANES differed in their wording, which may have introduced response bias. For instance, VIRGO assessed use of female hormones by including pills, shots, implants, patches, and vaginal creams, whereas NHANES included pills, injectables, patches, and creams. Fourthly, the imputation strategies using mode or median can underestimate variability, introduce bias, and does not account for uncertainty in missing values. Fifthly, residual confounding may persist due to differences between the VIRGO and NHANES populations, as VIRGO enrolled hospitalized patients with AMI whereas NHANES represents a community-based sample. Although adjustments were made for socioeconomic and cardiovascular risk factors, the observed associations may partly reflect broader social and metabolic risk clustering rather than isolated reproductive effects. Sixthly, we performed 1:1 matching between cases and controls only based on age. Though racial and socioeconomic differences were adjusted in the model, there may be residual confounding related to demographic and socioeconomic differences between the VIRGO and NHANES populations. This may reduce the study's power and limit the interpretability of the results. Conclusion This case-control study revealed the association of reproductive factors with AMI in young women. While most associations were mediated by traditional risk factors, hormone exposure may confer independent effect. Differences exist in risk profiles by menopausal status. These findings support the incorporation of reproductive history and hormone exposure into AMI prevention strategies in young women. Funding and disclosures The VIRGO study (NCT00597922) was supported by grant R01 HL081153 from the National Heart, Lung, and Blood Institute (NHLBI). In the past three years, Mitsuaki Sawano has been partially supported by research funding from Polybio, Pfizer, and Novartis through Yale University; he has also received lecture honoraria from Boehringer Ingelheim. Xiao Xu has received honoraria and travel funding from the AAGL. Harlan Krumholz has received options for Element Science and Identifeye and payments from F-Prime for advisory roles. He is a co-founder of and holds equity in Hugo Health, Refactor Health, and ENSIGHT-AI. He is associated with research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer. Yuan Lu received support from the Sentara Research Foundation, the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL69954 and R01HL169171), and the 10.13039/100006093Patient-Centered Outcomes Research Institute (under award HM-2022C2-28354) outside of the submitted work. The other authors report no financial support for the research, authorship, and/or publication of this article. CRediT authorship contribution statement Weilai Dong: Writing – original draft, Visualization, Formal analysis. Huanhuan Yang: Writing – review & editing, Formal analysis. Mitsuaki Sawano: Writing – review & editing. Shu-Xia Li: Writing – review & editing, Methodology. Xiao Xu: Writing – review & editing, Conceptualization. Karthik Murugiah: Writing – review & editing. Harlan M. Krumholz: Supervision. Yuan Lu: Writing – review & editing, Supervision, Methodology, Conceptualization. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Harlan Krumholz reports financial support was provided by National Heart Lung and Blood Institute. Harlan Krumholz reports a relationship with Element Science Inc, Identifeye, F-Prime that includes: consulting or advisory. Harlan Krumholz reports a relationship with Hugo Health, Refactor Health, and ENSIGHT-AI that includes: equity or stocks. Mitsuaki Sawano reports a relationship with Boehringer Ingelheim that includes: speaking and lecture fees. Mitsuaki Sawano reports a relationship with Polybio, Pfizer, and Novartis that includes: funding grants. Xiao Xu reports a relationship with AAGL that includes: speaking and lecture fees and travel reimbursement. Harlan Krumholz reports a relationship with Kenvue, Novartis, and Pfizer that includes: funding grants. Yuan Lu reports a relationship with National Heart, Lung, and Blood Institute of the National Institutes of Health that includes: funding grants. Yuan Lu reports a relationship with Patient-Centered Outcomes Research Institute that includes: funding grants. Yuan Lu reports a relationship with Sentara Research Foundation that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.